Please login to the form below
propofol
This page shows the latest propofol news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca sells rights to seven anaesthetics in $770m deal
topical anaesthetics Diprivan (propofol) and EMLA (lidocain and prilocaine), plus five local anaesthetics.
Latest news
-
R&D news in brief
SkyePharma and Endo halt Propofol IDD-DTM development. SkyePharma says it has agreed with US partner Endo to terminate joint development of Propofol IDD-DTM, an injectable anaesthetic and sedative that ... Under the terms of the December 2002 agreement,
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and Diprivan (propofol), a short acting intravenous sedative/ anaesthetic.
-
Pharma deals in February 2015
The sedative and analgesic propofol recall on the very day the acquisition was announced due, and not for the first time, to particulate iron embedded in the neck of a vial
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- Moderna inks R&D agreements with Vertex and Chiesi
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
